Establishing Avastin^© -based therapy as essential for the first-line treatment of metastatic non-squamous NSCLC

Avastin^© : proven and consistent efficacy in first-line NSCLC

• NSCLC accounts for >80% of all cases of lung cancer and is diagnosed at an advanced stage in the majority of patients.¹
• Tumour histology is of particular importance in selecting therapy for advanced NSCLC
  • NSCLC consists of both squamous and non-squamous histologies, the majority of non-squamous cases being adenocarcinomas.²
• Chemotherapy (platinum doublets) is the most commonly used approach in the treatment of NSCLC, but outcomes with chemotherapy have reached a plateau.³
• Avastin^© , in combination with platinum-doublet chemotherapy, is approved for the first-line treatment of patients with unresectable, advanced, metastatic or recurrent non-squamous NSCLC.
• The proven efficacy and favourable safety profile of first-line Avastin^© has been demonstrated in two large, randomised phase III clinical trials
  • Avastin^© delivers the longest survival time in non-squamous NSCLC
  • Avastin^© has limited impact on the side effects of chemotherapy.